New And Special Drugs
Atled (Fanregratinib) – Intrahepatic Cholangiocarcinoma | HongKong DengYue Medicine
Redemplo (Plozasiran) – FCS | HongKong DengYue Medicine
Yizekang (Izalontamab Brengitecan) – NPC/ESCC | HongKong DengYue Medicine
Qiyoukang (Gumokimab) – Plaque Psoriasis | HongKong DengYue Medicine
Lukeda (Rocbrutinib) – MCL | HongKong DengYue Medicine
Epkinly (Epcoritamab) – Follicular Lymphoma | HongKong DengYue Medicine
Blenrep (Belantamab Mafodotin) – Multiple Myeloma | HongKong DengYue Medicine
Hyrnuo (Sevabertinib) – NSCLC | HongKong DengYue Medicine
What Can We Offer You?
Generic drugs
Dedicated to providing high-quality, affordable medicines around the world
Vitamins and Supplements
A balanced diet by addressing different deficiencies with the right dosage
brand name medicines
DengYue Medicine as China Drug Import and Export Wholesaler, fills the gap between quality and quantity by adding some affordability
Fast-moving consumer goods
Stock a full range of products from sanitary napkins to foot care creams for your daily needs
non-prescription drugs
Flagship OTC brand - approved and accepted by global standards
Medical supplies and auxiliary supplies
Explore continually updated supplies, diagnostic equipment and essential tools
News
HongKong DengYue Medicine Wholesaler focus on medical trends and obtain new drug directions.
Targeted and Immunotherapy Drugs for Liver Cancer: Treatment Options and Latest Advances
Liver cancer, especially advanced hepatocellular carcinoma (HCC), is increasingly treated with targeted therapy and immunotherapy as important systemic treatment approaches. So, what are the targeted
What Are the Most Common Targeted Cancer Drugs? Key Targets and Treatment Uses
What are the most common targeted cancer drugs? Common targeted cancer drugs include therapies targeting EGFR, ALK, HER2, KRAS, BRAF, VEGF/VEGFR, PARP, and CDK4/6. The
Innovative PNH Drug Licancopan Approved in China: Oral CFB Inhibitor for Dual Hemolysis Control
On August 20, NMPA announced the approval of Licancopan Fumarate Capsules, a Class 1 innovative drug developed by Hengrui Pharma, for the treatment of adults
Anflekitug Approved in China: A New IL-1β Targeted Treatment Option for Acute Gouty Arthritis
On August 20, 2026, Anflekitug was approved in China as an innovative drug developed by Sunshine Guojian, providing a new IL-1β targeted treatment option for
China Innovative Oncology Drugs: 15 New Approvals in H1 2026
According to publicly available information, 38 innovative drugs were approved for marketing in China in the first half of 2026, including 31 domestically developed innovative
Felzartamab Approved for Multiple Myeloma: Another CD38 Monoclonal Antibody Enters the Chinese Market
Felzartamab is a CD38-targeting human monoclonal antibody, with Felzartamab approved for multiple myeloma in China and under clinical development for IgA nephropathy, primary membranous nephropathy,
Tinengotinib Approved for Cholangiocarcinoma in China, Addressing FGFR Inhibitor Resistance
Tinengotinib approved for cholangiocarcinoma marks an important advance for patients with FGFR2 fusion or rearrangement-positive disease who have progressed after FGFR inhibitor therapy. As a
Breast Cancer Drug List in China: Common Endocrine, Targeted, ADC, and Chemotherapy Drugs
The breast cancer drug list in China mainly includes endocrine therapy drugs, HER2-targeted drugs, CDK4/6 inhibitors, mTOR inhibitors, PARP inhibitors, antibody-drug conjugates (ADCs), chemotherapy drugs,
Fast And Safe Delivery
Global Transportation Express
Temperature-controlled Transport
Safe Transportation, GDP Compliant
